1 April 2022 - The April 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The April issue of the Schedule includes a few revised listings:

• Budesonide (Entocort) - new formulation
• Cabotegravir sodium (Vocabria) - new medicine
• Cabotegravir and rilpivirine (Cabenuva) - new combination product
• Elexacaftor with tezacaftor and ivacaftor and ivacaftor (Trikafta) - new combination product
• Empagliflozin (Jardiance) - new indication
• Fluticasone furoate with vilanterol trifenatate and umeclidinium bromide (Trelegy Ellipta) - new indication
• Olaparib (Lynparza) - new indication
• Siltuximab (Sylvant) - new medicine
• Trastuzumab (Herzuma) - new strength

Read Summary of PBS changes